Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trabeculectomy Remains Essential for Glaucoma Care.

Ophthalmology. Glaucoma·2026
Same author

Innovating global regulatory frameworks for generative AI in medical devices is an urgent priority.

NPJ digital medicine·2026
Same author

Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting.

JAMA ophthalmology·2025
Same author

Conjunctival histopathological changes associated with netarsudil 0.02.

Eye (London, England)·2025
Same author

Likelihood of Corneal Transplantation after Tube versus Trabeculectomy: An IRIS® Registry Study.

Ophthalmology. Glaucoma·2025
Same author

International partnership for governing generative artificial intelligence models in medicine.

Nature medicine·2025

Related Experiment Video

Updated: Mar 18, 2026

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

10.0K

Association between self-reported bupropion use and glaucoma: a population-based study.

Marissé Masís1, Caitlin Kakigi1, Kuldev Singh2

  • 1University of California San Francisco, San Francisco, California, USA.

The British Journal of Ophthalmology
|July 1, 2016
PubMed
Summary
This summary is machine-generated.

Long-term bupropion use may reduce glaucoma risk. This study found that individuals using bupropion for over a year had lower odds of self-reported glaucoma compared to non-users.

Keywords:
GlaucomaOptic NervePharmacologyPhysiologyTreatment other

More Related Videos

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.9K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K

Related Experiment Videos

Last Updated: Mar 18, 2026

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

10.0K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.9K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Public Health

Background:

  • Glaucoma is a leading cause of irreversible blindness worldwide.
  • Bupropion is a widely prescribed antidepressant and smoking cessation aid.
  • Understanding medication associations with eye diseases is crucial for patient care.

Purpose of the Study:

  • To examine the association between bupropion use and self-reported glaucoma.
  • To analyze this relationship in a nationally representative US population sample.

Main Methods:

  • Cross-sectional study using National Health and Nutrition Examination Survey (NHANES) data (2005-2008).
  • Included 6760 adults aged 40+ reporting glaucoma status and medication use.
  • Multivariate logistic regression analyzed the association between bupropion use duration and prevalent glaucoma, adjusting for covariates.

Main Results:

  • 108 participants reported bupropion use; 453 reported glaucoma.
  • Bupropion use exceeding one year was associated with decreased odds of self-reported glaucoma (adjusted OR=0.1, 95% CI 0.01-0.81).

Conclusions:

  • Extended bupropion use may be linked to a reduced risk of developing glaucoma.
  • Further research is warranted to confirm this potential protective association.